Cardiovascular disease and feminizing gender-affirming hormone therapy: Implications for the provision of safe and lifesaving care
{{output}}
Sex recorded at birth, gender identity, and feminizing gender-affirming hormone therapy (fGAHT) likely contribute to cardiovascular disease (CVD) risk in transgender women. Understanding the interplay of these factors is necessary for the provision of safe, af... ...
